Kidney Cancer

Oncology
14
Pipeline Programs
12
Companies
15
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
3
0
8
0
2
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
4100%
+ 13 programs with unclassified modality

Competitive Landscape

11 companies ranked by most advanced pipeline stage

Ipsen
IpsenChina - Tianjin
1 program
1
NivolumabPhase 4Monoclonal Antibody1 trial
Active Trials
NCT06934057Recruiting50Est. Apr 2028
Alliance Pharmaceuticals
3 programs
1
1
1
bevacizumabPhase 3Monoclonal Antibody1 trial
filgrastimPhase 21 trial
hypoxia-activated prodrug TH-302Phase 11 trial
Active Trials
NCT01497444Completed24Est. Nov 2019
NCT00027573Completed36Est. Jun 2006
NCT00072046Completed732Est. Nov 2012
Heidelberg Pharma
Heidelberg PharmaGermany - Ladenburg
1 program
1
girentuximabPhase 3Monoclonal Antibody1 trial
Active Trials
NCT00087022Completed864Est. Oct 2012
Knight Therapeutics
Knight TherapeuticsQC - Montréal
3 programs
3
EverolimusPhase 21 trial
cyclosporinePhase 21 trial
erlotinib hydrochloridePhase 21 trial
Active Trials
NCT00331409Completed23Est. Jan 2010
NCT00243009Terminated1Est. Apr 2006
NCT00425386Completed60Est. Mar 2014
Genentech
GenentechCA - Oceanside
2 programs
2
OSI-774Phase 2
bevacizumabPhase 2Monoclonal Antibody
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
1
OSI-774Phase 21 trial
Active Trials
NCT00193154Completed63Est. Mar 2014
Novartis
NovartisBASEL, Switzerland
1 program
1
ZoledronatePhase 21 trial
Active Trials
NCT00490698Completed11Est. Jan 2012
Bristol Myers Squibb
2 programs
1
MDX 1411Phase 11 trial
Participant Reported Outcomes and Treatment Experiences in Kidney CancerN/A1 trial
Active Trials
NCT04472663Completed5Est. Dec 2020
NCT00656734Completed27Est. Jun 2010
Amgen
AmgenTHOUSAND OAKS, CA
1 program
1
sorafenib tosylatePhase 11 trial
Active Trials
NCT00405366Completed30Est. Jul 2015
AT
Agile TherapeuticsNJ - Princeton
1 program
Partial NephrectomyN/A1 trial
Active Trials
NCT05363657Recruiting10,000Est. Dec 2028
Verona Pharma
Verona PharmaUK - London
1 program
robot-assisted partial nephrectomyN/A1 trial
Active Trials
NCT07065825Not Yet Recruiting100Est. Dec 2030

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
IpsenNivolumab
Heidelberg Pharmagirentuximab
Alliance Pharmaceuticalsbevacizumab
NovartisZoledronate
Knight Therapeuticserlotinib hydrochloride
Knight TherapeuticsEverolimus
Knight Therapeuticscyclosporine
AstraZenecaOSI-774
Alliance Pharmaceuticalsfilgrastim
Alliance Pharmaceuticalshypoxia-activated prodrug TH-302
Bristol Myers SquibbMDX 1411
Amgensorafenib tosylate
Verona Pharmarobot-assisted partial nephrectomy
Agile TherapeuticsPartial Nephrectomy
Bristol Myers SquibbParticipant Reported Outcomes and Treatment Experiences in Kidney Cancer

Clinical Trials (15)

Total enrollment: 12,026 patients across 15 trials

NCT06934057IpsenNivolumab

Cabozantinib and Nivolumab Among Older Patients With Renal Cell Carcinoma

Start: May 2025Est. completion: Apr 202850 patients
Phase 4Recruiting
NCT00087022Heidelberg Pharmagirentuximab

Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer

Start: Jul 2004Est. completion: Oct 2012864 patients
Phase 3Completed
NCT00072046Alliance Pharmaceuticalsbevacizumab

Interferon Alfa-2b With or Without Bevacizumab in Treating Patients With Advanced Renal Cell Carcinoma (Kidney Cancer)

Start: Oct 2003Est. completion: Nov 2012732 patients
Phase 3Completed
NCT00490698NovartisZoledronate

Zoledronate With Atorvastatin in Renal Cell Carcinoma

Start: Oct 2006Est. completion: Jan 201211 patients
Phase 2Completed
NCT00425386Knight Therapeuticserlotinib hydrochloride

Sunitinib and Erlotinib in Treating Patients With Unresectable or Metastatic Kidney Cancer

Start: Aug 2006Est. completion: Mar 201460 patients
Phase 2Completed
NCT00331409Knight TherapeuticsEverolimus

Everolimus and Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Kidney Cancer

Start: Jan 2006Est. completion: Jan 201023 patients
Phase 2Completed
NCT00243009Knight Therapeuticscyclosporine

Fludarabine and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Metastatic Kidney Cancer That Cannot Be Removed By Surgery

Start: Jun 2005Est. completion: Apr 20061 patients
Phase 2Terminated
NCT00193154AstraZenecaOSI-774

OSI-774 and Bevacizumab in the Treatment of Patients With Metastatic Renal Cell Carcinoma

Start: Feb 2003Est. completion: Mar 201463 patients
Phase 2Completed
NCT00027573Alliance Pharmaceuticalsfilgrastim

Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic or Unresectable Kidney Cancer

Start: Oct 2001Est. completion: Jun 200636 patients
Phase 2Completed
NCT01497444Alliance Pharmaceuticalshypoxia-activated prodrug TH-302

Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients With Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed By Surgery

Start: May 2012Est. completion: Nov 201924 patients
Phase 1Completed
NCT00656734Bristol Myers SquibbMDX 1411

Study of MDX-1411 Given Every 14 Days With Pre-medications to Subjects With Clear Cell Kidney Cancer.

Start: Apr 2008Est. completion: Jun 201027 patients
Phase 1Completed
NCT00405366Amgensorafenib tosylate

Sorafenib in Treating Patients Undergoing Surgery for Stage II, Stage III, or Stage IV Kidney Cancer

Start: Nov 2006Est. completion: Jul 201530 patients
Phase 1Completed
NCT07065825Verona Pharmarobot-assisted partial nephrectomy

Tumor Rupture During Robotic Partial Nephrectomy

Start: Sep 2025Est. completion: Dec 2030100 patients
N/ANot Yet Recruiting
NCT05363657Agile TherapeuticsPartial Nephrectomy

International REgistry of COnservative or Radical Treatment of Localized Kidney Tumors

Start: Jan 2022Est. completion: Dec 202810,000 patients
N/ARecruiting
NCT04472663Bristol Myers SquibbParticipant Reported Outcomes and Treatment Experiences in Kidney Cancer

Participant Reported Outcomes and Treatment Experiences in Kidney Cancer

Start: Jul 2020Est. completion: Dec 20205 patients
N/ACompleted

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
2m ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
2m ago

Office Administrator

SystImmune
2m ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
13m ago

Working Student Office Management Support (m/f/d)

Mindpeak
Hamburg
16m ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
16m ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs — potential near-term approvals
2 actively recruiting trials targeting 12,026 patients
12 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)